
A new report titled Research on China Cardiovascular Drugs Industry 2014-2018, says that, in the next 10 years, there is a potential for the growth in cardiovascular diseases treatment field.
It is predicted that the growth rate will be of more than 20% from 2014 to 2018. This report, added to the offering of MarketReportsChina.com, estimates that the sales of cardiovascular drugs in China in 2014 will reach about 22 billion renminbi ($3.52 billion), and the figure will be 45 billion renminbi by 2018.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze